Advertisement
Research Article| Volume 20, ISSUE 5, P539-545, May 1985

Platelet alpha-2-adrenergic dysfunction in negative symptom schizophrenia: A preliminary study

DOI:https://doi.org/10.1016/0006-3223(85)90025-3
Platelet alpha-2-adrenergic dysfunction in negative symptom schizophrenia: A preliminary study
Previous ArticleCeruletide for schizophrenia: A double-blind study
Next ArticleA controlled clinical trial of l-tryptophan in acute mania
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      The specific binding to platelet membranes (Bmax) of 3H-clonidine, and alpha-2 agonist, and 3H-yohimbine, an alpha-2 antagonist, was measured in nine drug-free male schizophrenic patients and repeated after 2 weeks of chlorpromazine (CPZ) treatment. Patients with a lower pretreatment Bmax for 3H-clonidine showed a significantly smaller change in Bmax after treatment, less improvement in their clinical state, as indicated by the change in the Global Assessment Scale (GAS), and a lower posttreatment GAS. Also, they had a significantly higher score for negative symptoms on the Affect Rating Scale both before and after treatment. These findings suggest that schizophrenic patients with relatively subsensitive platelet alpha-2-adrenergic receptors, as measured by 3H-clonidine binding, tend to have more negative symptoms and a diminished alpha receptor binding response and diminished clinical response to CPZ. There were no clinical correlations to 3H-yohimbine binding.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Ackenheil M.
        • Albus M.
        • Gross R.
        • et al.
        On the importance of norepinephrine (NE) and receptors in schizophrenia.
        in: Collegium Internationale Neuropsychopharmacologicum, CINP Congress. I. 1982: 3 (Jerusalem, Israel (abstr 12))
        • American Psychiatric Association
        ed 3. DSM-III. Diagnostic and Statistical Manual of Mental Disorders. APA, Washington, DC1980
        • Andreasen N.C.
        Affective flattening and criteria for schizophrenia.
        Am J Psychiatry. 1979; 136: 944-947
        • Andreasen N.C.
        • Olsen S.
        Negative vs positive schizophrenia.
        Arch Gen Psychiatry. 1982; 39: 789-794
        • Castellani S.
        • Ziegler M.H.
        • van Kammen D.P.
        • et al.
        Plasma norepinephrine and dopamine ß-hydroxylase activity in schizophrenia.
        Arch Gen Psychiatry. 1982; 39: 1145-1149
        • Crow T.J.
        Molecular pathology of schizophrenia: More than one disease process?.
        Br Med J. 1980; 2801: 1-9
        • Crow T.J.
        • Baker H.F.
        • Cross A.J.
        • et al.
        Monoamine mechanism in chronic schizophrenia: Post-mortem neurochemical findings.
        Br J Psychiatry. 1979; 134: 249-256
        • Farley I.V.
        • Price K.S.
        • McCoullough E.
        • et al.
        Norepinephrine in chronic paranoid schizophrenia: Above normal levels in limbic forebrain.
        Science. 1978; 200: 456-458
        • Garcia-Seville J.A.
        • Hollingsworth P.J.
        • Smith C.B.
        Alpha 2 adrenoreceptors on human platelets: Selective labeling by 3H clonidine and 3H yohimbine and competitive inhibition by antidepressant drugs.
        Eur J Pharmacol. 1981; 74: 329
        • Hamilton M.
        A Rating Scale for Depression.
        J Neurol Neurosurg Psychiatry. 1960; 23: 56-62
        • Hoffman B.B.
        • Michel T.
        • Brenneman T.B.
        • et al.
        Interactions of agonists with platelet alpha 2-adrenergic receptors.
        Endocrinology. 1982; 110: 926-932
        • Hornykiewicz O.
        Brain catecholamine in schizophrenia—A good case for noradrenaline.
        Nature. 1982; 299: 484-485
        • Kafka M.S.
        • van Kammen D.P.
        Alpha-adrenergic receptor functions in schizophrenics.
        Arch Gen Psychiatry. 1983; 20: 269-270
        • Lake C.R.
        • Sternberg D.E.
        • van Kammen D.P.
        • et al.
        Schizophrenia: Elevated cerebrospinal fluid norepinephrine.
        Science. 1980; 207: 331-333
        • Matussek M.
        • Ackenheil M.
        • Hippius H.
        • et al.
        Effect of clonidine on growth hormone release in psychiatric patients and controls.
        Psychiatry Res. 1980; 2: 25-36
        • Peroutka S.J.
        • Pritchard D.C.
        • Greenberg D.S.
        • et al.
        Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain.
        Neuropharmacology. 1977; 16: 549-556
        • Rice H.E.
        • Smith C.B.
        • Silk K.R.
        • et al.
        Platelet alpha 2-adrenergic receptors before and after phenothiazine treatment.
        Psychiatry Res. 1984; 12: 69-77
        • Rotrosen J.
        • Miller A.D.
        • Mandio D.
        • et al.
        Prostaglandins, platelets and schizophrenia.
        Arch Gen Psychiatry. 1980; 37: 1047-1057
        • Spitzer R.
        • Gibben M.
        • Endicott J.
        • Robbin E.
        Research Diagnostic Criteria (RDC).
        ed 3. Biometrics Research, New York1977
        • Steer M.
        • Wood A.
        Regulation of human platelet adenylate cyclase by epinephrine, prostaglandin and guanine nucleotides.
        J Biol Chem. 1979; 254: 10781-10797
        • Sternberg D.E.
        • Charney D.S.
        • Heninger G.R.
        • et al.
        Impaired presynaptic regulation of norepinephrine in schizophrenia.
        Arch Gen Psychiatry. 1982; 39: 285-289
        • van Kammen D.P.
        • Antelman S.
        Mini-review: Impaired noradrenergic transmission in schizophrenia.
        Life Sci. 1984; 34: 1403-1413
        • van Kammen D.P.
        • Mann L.S.
        • Sternberg D.E.
        • et al.
        Dopamine ß-hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy.
        Science. 1983; 220: 974-976
        • Weinberger R.L.
        • Torrey E.F.
        • Neophytides A.N.
        • et al.
        Lateral cerebral ventricular enlargement in chronic schizophrenia.
        Arch Gen Psychiatry. 1979; 36: 735-739

      Article info

      Publication history

      Received in revised form: November 24, 1984
      Received: April 9, 1984

      Identification

      DOI: https://doi.org/10.1016/0006-3223(85)90025-3

      Copyright

      © 1985 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX